Docetaxel in advanced non-small cell lung cancer.

about

miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.

P2860

Q36610611-CCA7764F-8D20-4CC1-8B56-B75FF81AE50B Q38546598-D235DF67-AAE6-4A08-87B3-0D7B5779E9DB Q41676866-4C9EC843-B466-4B18-AD38-1044671B19D9

P2860

Docetaxel in advanced non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q36066126

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Docetaxel in advanced non-small cell lung cancer.

@ast

Docetaxel in advanced non-small cell lung cancer.

@en

type

Item

label

Docetaxel in advanced non-small cell lung cancer.

@ast

Docetaxel in advanced non-small cell lung cancer.

@en

prefLabel

Docetaxel in advanced non-small cell lung cancer.

@ast

Docetaxel in advanced non-small cell lung cancer.

@en

P1476

Docetaxel in advanced non-small cell lung cancer

@en

P2093

Heather Wakelee

http://www.w3.org/2001/XMLSchema#string

Sakkaraiappan Ramalingam

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Cancer statistics, 2004

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.

Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.

A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.

Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

P304

13-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.5.1.13

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chandra Belani

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15757434

http://www.w3.org/2001/XMLSchema#string

Docetaxel in advanced non-small cell lung cancer.

about

P2860

P2860

Docetaxel in advanced non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698